Topic: antibody-drug conjugates
Despite their promise, antibody-drug conjugates have been tough to bring to market, but a U.K. biotech wants to change that.
On the heels of an $85 million private round, Sutro Biopharma has filed to raise up to $75 million in its IPO.
Sutro Biopharma reeled in an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline.
The FDA has placed a partial hold on Mersana’s lead candidate XMT-1522 after a patient death in a phase 1 trial, causing its shares to plunge.
Vaccinex filed a $46 million Nasdaq IPO to support its development of antibodies and conjugates targeting neurodegenerative diseases and cancer.
NBE will use the money to start testing anti-ROR1 antibody-drug conjugate NBE-002 in solid tumor patients.
Celldex culled another two R&D projects after its midstage failure in April, and now says it will focus its efforts mainly on two cancer antibodies.
AbbVie has terminated an early-stage trial of an antibody-drug conjugate for solid tumors.
ADC Therapeutics has dropped a midpipeline candidate for HER2-positive cancers because of toxicity issues in a phase 1 trial in solid tumors.
AstraZeneca is seeking approval of moxetumomab pasudotox in HCL patients who have undergone at least two prior lines of treatment.